非FDG示踪剂在肺癌中的作用?
本文综述了非FDG PET放射性药物在肺癌影像中的应用现状,涵盖靶向DNA合成、氨基酸代谢、血管生成和缺氧的示踪剂,指出这些示踪剂虽在特定临床问题或作为FDG补充工具方面有初步应用,但未能广泛进入临床常规;FAPI因作用机制和初步试验显示出在肺癌中优于或媲美FDG的潜力。
要点
- FDG是肿瘤影像最常用的放射性示踪剂,但对多种肺癌组织病理类型特异性和敏感性低,且正常组织背景摄取高。
- 靶向DNA合成、氨基酸代谢、血管生成或缺氧的放射性药物经广泛研究,可用于特定临床问题或作为FDG的补充影像工具。
- FAPI在肺癌影像的初步试验中显示出优于或媲美FDG的诊断性能潜力。
核心结论
- 非FDG示踪剂中,靶向DNA合成、氨基酸代谢、血管生成或缺氧的放射性药物未能获得广泛临床应用,而FAPI在肺癌影像中显示出优于或媲美FDG诊断性能的潜力。
研究设计与样本
- 本文为综述,总结了当前PET放射性药物、不同影像方法及其在肺癌影像中的潜在获益与临床应用。
主要发现
- FDG因低特异性和低敏感性以及对多种肺癌组织病理类型的高正常组织背景摄取,在肺癌影像中存在诸多严重陷阱。
- 靶向DNA合成、氨基酸代谢、血管生成或缺氧的放射性药物虽经广泛研究并出现针对特定临床问题的适应证,但未能获得广泛临床应用。
- FAPI基于其作用机制和肺癌影像的初步试验,显示出优于或媲美FDG影像的诊断性能潜力。
局限性
- 靶向DNA合成、氨基酸代谢、血管生成或缺氧的示踪剂尽管有初步令人鼓舞的结果,但未能获得广泛临床应用和接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since the introduction of PET/CT hybrid imaging about two decades ago the landscape of oncological imaging has fundamentally changed, opening a new era of molecular imaging with emphasis on functional characterization of biological processes such as metabolism, cellular proliferation, hypoxia, apoptosis, angiogenesis and immune response. The most commonly assessed functional hallmark of cancer is the increased metabolism in tumor cells due to well-known Warburg effect, because of which FDG has been the most employed radiotracer, the so-called pan-cancer agent, in oncological imaging. However, several limitations such as low specificity and low sensitivity for several histopathological forms of lung cancer as well as high background uptake in the normal tissue of FDG imaging lead to numerous serious pitfalls. This restricts its utilization and diagnostic value in lung cancer imaging, even though this is currently considered to be the method of choice in pulmonary cancer imaging. Accurate initial tumor staging and therapy response monitoring with respect to the TNM criteria plays a crucial role in therapy planning and management in patients with lung cancer. To this end, many efforts have been made for decades to develop novel PET radiopharmaceuticals with innovative approaches that go beyond the assessment of increased glycolytic activity alone. Radiopharmaceuticals targeting DNA synthesis, amino acid metabolism, angiogenesis, or hypoxia have been extensively studied, leading to the emergence of indications for specific clinical questions or as a complementary imaging tool alongside existing conventional or FDG imaging. Nevertheless, despite some initial encouraging results, these tracers couldn't gain a widespread use and acceptance in clinical routine. However, given its mechanism of action and some initial pilot studies regarding lung cancer imaging, FAPI has emerged as a very promising alternative tool that could provide superior or comparable diagnostic performance to FDG imaging in lung cancer entities. Thus, in this review article, we summarized the current PET radiopharmaceuticals, different imaging approaches and discussed the potential benefits and clinical applications of these agents in lung cancer imaging.
引用
- Novruzov E, Mori Y, Antke C, et al. A Role of Non-FDG Tracers in Lung Cancer? Semin Nucl Med. 2022. PMID: 35803770. doi:10.1053/j.semnuclmed.2022.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。